Skip to main content
Sandra Silberman, MD, Oncology, Durham, NC

SandraLSilbermanMD

Oncology Durham, NC

Vice President Translational Medicine Attending Physician Durham VAMC

Dr. Silberman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Silberman's full profile

Already have an account?

  • Office

    508 Fulton St
    Durham, NC 27705
    Phone+1 828-257-2333

Education & Training

  • Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1988 - 1992
  • NYU Grossman School of Medicine
    NYU Grossman School of MedicineResidency, Internal Medicine, 1985 - 1987
  • Weill Cornell Medicine
    Weill Cornell MedicineClass of 1985

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 2016 - 2023
  • NJ State Medical License
    NJ State Medical License 2002 - 2017
  • CT State Medical License
    CT State Medical License 1992 - 2005
  • American Board of Internal Medicine Internal Medicine

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDA...
    Sandra L Silberman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Press Mentions

  • Moleculin Announces Publication of Data Supporting Development of Non-Cardiotoxic Anthracycline for the Treatment of Cancer in Peer-Reviewed European Journal of Cancer
    Moleculin Announces Publication of Data Supporting Development of Non-Cardiotoxic Anthracycline for the Treatment of Cancer in Peer-Reviewed European Journal of CancerMarch 9th, 2023
  • CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Has Potential to Make History in Battle Against Deadly Brain Cancer with Berubicin
    CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Has Potential to Make History in Battle Against Deadly Brain Cancer with BerubicinDecember 12th, 2022
  • CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Expanding Scope of Potentially Pivotal Study as Part of Clinical Program to Develop GBM Treatment
    CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Expanding Scope of Potentially Pivotal Study as Part of Clinical Program to Develop GBM TreatmentAugust 2nd, 2022
  • Join now to see all